-
1
Dazucorilant, an experimental drug by Corcept Therapeutics, did not meet the main goal of slowing the decline in motor skills and functional criteria for ALS patients in a mid-stage trial.
-
2
Patients receiving dazucorilant experienced more gastrointestinal upset than those receiving the placebo.
-
3
No deaths were observed in the 300 mg dose group of dazucorilant, while five deaths were reported in the placebo group.
-
4
Complete study results will be presented next year.
-
5
An open-label, long-term extension study will continue, assessing overall survival in March 2025.
Original Source(s)
Related Content
Medical Oddities: For the Birds—and the Brain
Birds for brains, blackout laughs, anti-aging tea, thin air, muscle memory—and torn marriages, all with a clinical touch this week.
by Teraya Smith
February 25, 2026
-
6 min
How Midlife Diet Relates to Cognitive Aging
Healthier dietary patterns were associated with better later-life cognitive outcomes
by Henry Thomas
February 24, 2026
-
3 min
Experts Prioritize 3 Drugs for Alzheimer's
A global expert consensus identifies three repurposed drugs, including the shingles vaccine, as top candidates for Alzheimer disease clinical trials
by Kerri Miller
February 20, 2026
-
5 min
